Ankasa Regenerative Therapeutics
La Jolla, US · Founded 2014 · Delaware corporation · 2 known investors
Ankasa is developing ART352-L, a regenerative medicine designed to enhance bone formation in reconstructive surgeries, with initial focus on spinal fusion procedures to treat degenerative disc disease. The therapy aims to improve healing outcomes and reduce revision surgeries for patients requiring bone reconstruction.
Founders & leadership
Ankasa Regenerative Therapeutics was founded in 2014 by Sanford J. Madigan, Ph.D. and Jill A. Helms, D.D.S., Ph.D..
SJ
Sanford J. Madigan, Ph.D.Co-Founder, Chief Executive Officer
JA
Jill A. Helms, D.D.S., Ph.D.Co-founder, Former CSO, currently Senior Advisor
DD
Douglas DownsExecutive
SJ
Sanford J. MadiganCEO
Board
KK
Kevin KinsellaBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$15.5M disclosed across 2 rounds · 2015–2020
▶$6MraisedOct 2020 · 4 investors · BiotechnologyRule 506(b)
▶$6MraisedOct 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sanford J. MadiganExecutive Officer, Director
- Kevin KinsellaDirector
- Andre Kobelt, Ph.D.Director
- Tighe ReardonExecutive Officer
- Offering amount
- $12M
- Amount sold
- $6M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.5MraisedAug 2015 · 5 investors · PharmaceuticalsRule 506(b)
▶$9.5MraisedAug 2015 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Douglas DownsExecutive Officer, Director
- Kevin KinsellaDirector
- Sanford J. MadiganExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $9.5M
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Ankasa Regenerative Therapeutics do?
- Ankasa is developing ART352-L, a regenerative medicine designed to enhance bone formation in reconstructive surgeries, with initial focus on spinal fusion procedures to treat degenerative disc disease. The therapy aims to improve healing outcomes and reduce revision surgeries for patients requiring bone reconstruction.
- Who founded Ankasa Regenerative Therapeutics?
- Ankasa Regenerative Therapeutics was founded by Sanford J. Madigan, Ph.D., Jill A. Helms, D.D.S., Ph.D. in 2014.
- Who are Ankasa Regenerative Therapeutics's investors?
- Ankasa Regenerative Therapeutics's investors include Correlation Ventures, Stanford University.
- How much funding has Ankasa Regenerative Therapeutics raised?
- Ankasa Regenerative Therapeutics has disclosed $15.5M raised across 2 rounds.
- Where is Ankasa Regenerative Therapeutics headquartered?
- Ankasa Regenerative Therapeutics is headquartered in La Jolla, US.